Article Figures & Data
Figures
- Figure 1.
Four-year drug survival rates of each tumor necrosis factor drug. The number of patients taking the therapy (patients at risk) and the number of withdrawals (events) at each year are shown. ***p < 0.0001.
- Figure 2.
Four-year drug survival rates of anti-tumor necrosis factor drugs by main reasons of discontinuation. AE: adverse events. ***p < 0.0001.
Tables
- Table 1.
Demographic and disease characteristics of the patients at baseline. Kruskal-Wallis nonparametric test was used for continuous variables and the chi-squared test for categorical variables.
Characteristic Adalimumab, n = 324, F: 273, M: 51 Etanercept, n = 311, F: 268, M: 43 Infliximab, n = 218, F: 172, M: 46 Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR) p Age, yrs 54.5 (12) 55.4 (19) 53.5 (14) 54.4 (19) 51.9 (13) 52.5 (19) 0.06 Latency, mo 9.6 (9.0) 7.7 (12) 10.0 (8.6) 7.9 (11) 8.8 (7.8) 6.8 (12) 0.19 Disease duration, yrs 11.5 (8.8) 9.9 (11) 10.7 (8.6) 8.7 (10) 9.9 (7.7) 8.3 (12) 0.17 VAS pain, 0–100 66.8 (19) 70 (24) 70.7 (22) 71 (38) 67.1 (24) 70 (35) 0.23 ESR, mm/h 35.7 (22) 30 (27) 40.3 (22) 38 (33) 40.2 (24) 35 (31) 0.06 RF, % 68 70 76 0.08 HAQ 1.28 (0.5) 1.2 (0.7) 1.6 (0.7) 1.6 (1.0) 1.5 (0.6) 1.4 (1.0) 0.03 DAS28 5.37 (1.5) 5.65 (1.8) 5.71 (1.5) 5.98 (1.8) 5.6 (1.4) 5.8 (1.4) 0.04 Glucocorticoid, baseline, % 29 44 30 0.06 DMARD before, % 97 99 96 0.19 DMARD baseline, % 25 31 44 0.01 MTX 78 78 81 HCQ 11 11 7 Leflunomide 8 8 5 Sulfasalazine 1 1 4 Cyclosporine 1 4 1 Comorbidities, % 33 46 21 0.01 -
VAS: visual analog scale; ESR: erythrocyte sedimentation rate; RF: rheumatoid factor; HAQ: health assessment questionnaire; DAS28: Disease Activity Score based on 28 joints; DMARD: disease-modifying antirheumatic drugs; MTX: methotrexate; HCQ: hydroxychloroquine; IQR: interquartile range.
-
- Table 2.
EULAR responses observed with etanercept (ETA), adalimumab (ADA), and infliximab (INF) at 1, 2, 3, and 4 years.
EULAR Responses Adalimumab Etanercept Infliximab p (chi-square test) N (%) N (%) N (%) 1 year None 52 (25.7) 31 (16.6) 33 (20.2) < 0.01 ETA vs ADA Moderate 89 (44.0) 73 (37.8) 75 (46.0) < 0.01 ETA vs INF Good 61 (30.2) 89 (46.1) 55 (33.7) < 0.01 ETA vs ADA 2 years None 31 (20.8) 26 (16.9) 18 (14.5) NS Moderate 50 (33.5) 49 (32.0) 52 (41.9) < 0.01 ETA vs INF Good 68 (45.6) 78 (50.9) 54 (43.5) NS 3 years None 25 (19.5) 12 (9.1) 14 (14.1) < 0.01 ETA vs ADA Moderate 46 (35.9) 43 (32.8) 38 (38.3) NS Good 57 (44.5) 76 (58.0) 47 (47.4) NS 4 years None 80 (39.6) 49 (23.2) 56 (33.1) < 0.01 ETA vs ADA or INF Moderate 62 (30.6) 54 (25.5) 54 (31.9) NS Good 60 (29.7) 108 (51.1) 59 (34.9) < 0.01 ETA vs ADA or INF -
EULAR: European League Against Rheumatism; NS: not significant.
-
- Table 3.
Odds ratios of anti-TNF-α therapy survival at 4 years. Results of various univariate and multivariate logistic regression analyses. Final multivariate models were found by stepwise regression.
Univariate Multivariate Baseline Variables OR (95% CI) p OR (95% CI) p Sex: female vs male 1.15 (0.79–1.65) 0.46 1.3 (0.85–1.97) 0.22 Disease duration, yrs 0.99 (0.69–1.00) 0.054 0.98 (0.96–0.99) 0.02 ESR 1.00 (0.99–1.00) 0.69 1.01 (0.99–1.02) 0.14 DAS28 0.99 (0.90–1.09) 0.85 0.95 (0.85–1.06) 0.37 Comorbidities: yes vs no 0.67 (0.50–0. 87) 0.003 0.77 (0.56–1.05) 0.10 Glucocorticoids: yes vs no 0.76 (0.57–1.00) 0.05 1.18 (0.83–1.67) 0.39 DMARD: yes vs no 0.51 (0.38–0.68) 0.0001 0.64 (0.43–0.93) 0.02 MTX: yes vs no 0.61 (0.46–0.81) 0.0007 0.58 (0.41–0.82) 0.02 -
TNF: tumor necrosis factor; ESR: erythrocyte sedimentation rate; DAS28: Disease Activity Score based on 28 joints; DMARD: disease-modifying antirheumatic drugs; MTX: methotrexate.
-
In this issue
